Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eikon Therapeutics
VA Office of Research and Development
Novartis
University of Cincinnati
ImmunityBio, Inc.
Medicenna Therapeutics, Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
Peking University People's Hospital